Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

SAN DIEGO, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the third quarter ended September 30, 2010.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO)

"Halozyme achieved further clinical advances during the third quarter as we began additional studies for our Ultrafast Insulin and PEGPH20 proprietary programs," said Jonathan Lim, M.D., Halozyme's president and CEO. "In addition, we are excited by the continuing progress of our partners as Baxter and Roche presented positive data at medical meetings from their clinical trials for subcutaneous immunoglobulin and Herceptin SC, products that utilize our core rHuPH20 enzyme technology."

Third Quarter 2010 and Recent Business Highlights

  • Halozyme began patient dosing for two Phase 2 Ultrafast Insulin treatment studies that utilize rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®. Diabetes patients enrolled in these trials will receive an insulin analog alone and the Analog-PH20 treatment for 12 weeks each.
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/16/2014)... cell phones to cars and flashlights, batteries play ... technology companies constantly are seeking ways to improve ... time using a water-based solution, researchers at the ... more efficient nuclear battery that could be used ... source in automobiles and also in complicated applications ...
    (Date:9/16/2014)... 16, 2014 BlueInGreen® , ... efficient method for delivering dissolved gases into liquids, ... as a manufacturer’s representative firm to its ... products for municipal water and wastewater applications in ... H2Flow was founded in 1992 and serves Quebec ...
    (Date:9/16/2014)... Sept. 16, 2014  Donald Fresne, President and CEO of ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl (European ... at Inserm, the French institute of health and medical research. ... at the Curie Institute, Orsay, France , ...
    (Date:9/16/2014)... 16, 2014  The Council for Entrepreneurial Development ... in the country, today released a mid-year update ... It showed that in the first ... startups in the technology, life science, advanced ... from a variety of sources. Significant investment in technology ...
    Breaking Biology Technology:BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
    ... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
    ... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
    ... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
    Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2
    (Date:9/16/2014)... Sept. 16, 2014  Valencell, Inc., a leader in ... one of 18 "Showcase Companies" representing North ... annual CED Tech Venture Conference on September 16-17 th ... Center in Raleigh, North Carolina . ... a discussion during the "Digital Health Spotlight Sector" on ...
    (Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
    (Date:9/15/2014)... a common epilepsy drug to a morphine regimen can ... Moreover, the combination can reduce the dosage of the ... of pain researchers at Indiana University. , The result ... pain, a difficult-to-treat condition often felt in the arms ... "There is a huge unmet need for better treatments ...
    Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
    ... ago, the German Physical Society (DPG) has introduced the ... interdisciplinary applications of physics. The Prize, endowed with 5000 ... instrument to encourage research in this direction. This ... Max Planck Institute for Evolutionary Biology in Pln. He ...
    ... , New Rochelle, NY -- A novel method for ... help advance research on tissue engineering and regeneration, as ... Part C, Methods, a peer-reviewed journal from Mary Ann ... free online at the Tissue Engineering website ...
    ... proteins that actively pump a wealth of molecules across ... functions in humans. Genetic defects in ABC transporters can ... cystic fibrosis, and certain ABC transporters also cause resistance ... increased amounts of ABC transporters that pump chemotherapeutic substances ...
    Cached Biology News:'Young Scientist Award for Socio- and Econophysics 2012' for Arne Traulsen 2
    These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
    Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
    Mycoplasma and virus tested...
    Mycoplasma and virus tested...
    Biology Products: